A Comparison of Serum Copper Levels in Patients with Papillary Thyroid Carcinoma, Nodular Goiter, and Healthy Volunteers

Prachya  Maneeprasopchoke; Phoupong  Phousamran; Warut  Pongsapich; Paveena  Pithuksurachai; Jakrit  Worrakulpanit; Tippanate  Keawvijit; Naravat  Poungvarin; Kanchana  Amornpichetkul; Cheerasook  Chongkolwatana

doi:10.33192/smj.v75i1.260528

Authors

Prachya Maneeprasopchoke Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Phoupong Phousamran Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Warut Pongsapich Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Paveena Pithuksurachai Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Jakrit Worrakulpanit Department of Otorhinolaryngology, Bhumibol Adulyadej Hospital, Bangkok
Tippanate Keawvijit Clinical Toxicology Laboratory, Siriraj Poison Control Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Naravat Poungvarin Department of Clinical Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Kanchana Amornpichetkul Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Cheerasook Chongkolwatana Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok

DOI:

https://doi.org/10.33192/smj.v75i1.260528

Keywords:

Serum copper (Cu), nodular goiter, papillary thyroid carcinoma, thyroid cancer, BRAF mutation

Abstract

Objective: Serum copper (Cu) is an essential trace element that plays a key role in thyroid hormone production. An inappropriate level of serum Cu might be related to development of both benign and malignant thyroid neoplasm. Nodular goiter and papillary thyroid carcinoma (PTC) are common benign and malignant tumors of the thyroid, respectively. This study aims to compare the serum Cu levels of healthy women with women with PTC or nodular goiter.

Materials and Methods: A total of 205 Thai women were recruited for this cross-sectional study. The reference group was comprised of 100 healthy volunteers. There were 61 nodular goiter and 41 PTC patients that had been treated with surgery. Serum Cu was measured using an atomic absorption spectrophotometer and the three groups were compared.

Results: The serum Cu levels of the PTC, nodular goiter and the reference group were 0.93 (0.85, 1.11) μg/ml, 1.03 (0.90, 1.14) μg/ml and 0.97 (0.80, 1.11) μg/ml, respectively. The results were not statistically different (P = 0.10). A post hoc subgroup analysis in the PTC group showed only serum Cu levels were significantly higher in the blood vessel invasion group (P = 0.02).

Conclusion: The serum Cu levels of patients with PTC and nodular goiter were not different and did not differ significantly from the reference group. Despite related to with only one pattern of histopathologically aggressive PTCBlood vessel invasion, serum Cu levels cannot be used as an assistive tool for diagnosis and the prognosis of PTC.

References

Goyal MM, Kalwar AK, Vyas RK, Bhati A. A study of serum zinc, selenium and copper levels in carcinoma of esophagus patients. Indian J Clin Biochem. 2006;21(1):208-10.

Margalioth EJ, Udassin R, Cohen C, Maor J, Anteby SO, Schenker JG. Serum copper level in gynecologic malignancies. Am J Obstet Gynecol. 1987;157(1):93-6.

Lener MR, Scott RJ, Wiechowska-Kozlowska A, Serrano-Fernandez P, Baszuk P, Jaworska-Bieniek K, et al. Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer. Cancer Res Treat. 2016;48(3):1056-64.

Fisher GL, Spitler LE, McNeill KL, Rosenblatt LS. Serum copper and zinc levels in melanoma patients. Cancer. 1981;47(7):1838-44.

Mulware SJ. Trace elements and carcinogenicity: a subject in review. 3 Biotech. 2013;3(2):85-96.

Gullino PM, Ziche M, Alessandri G. Gangliosides, copper ions and angiogenic capacity of adult tissues. Cancer Metastasis Rev. 1990;9(3):239-51.

Fisher GL, Shifrine M. Hypothesis for the mechanism of elevated serum copper in cancer patients. Oncology. 1978;35(1):22-5.

Tapiero H, Townsend DM, Tew KD. Trace elements in human physiology and pathology. Copper. Biomed Pharmacother. 2003;57(9):386-98.

Zhu S, Shanbhag V, Wang Y, Lee J, Petris M. A Role for The ATP7A Copper Transporter in Tumorigenesis and Cisplatin Resistance. J Cancer. 2017;8(11):1952-8.

Coates RJ, Weiss NS, Daling JR, Rettmer RL, Warnick GR. Cancer risk in relation to serum copper levels. Cancer Res. 1989;49(15):4353-6.

Harris ED. Copper homeostasis: the role of cellular transporters. Nutr Rev. 2001;59(9):281-5.

Shen F, Cai WS, Li JL, Feng Z, Cao J, Xu B. The Association Between Serum Levels of Selenium, Copper, and Magnesium with Thyroid Cancer: a Meta-analysis. Biol Trace Elem Res. 2015;167(2):225-35.

Ishida S, Andreux P, Poitry-Yamate C, Auwerx J, Hanahan D. Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc Natl Acad Sci U S A. 2013;110(48):19507-12.

Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal. 2011;15(6):1583-606.

Araya M, Pizarro F, Olivares M, Arredondo M, Gonzalez M, Mendez M. Understanding copper homeostasis in humans and copper effects on health. Biol Res. 2006;39(1):183-7.

Bonham M, O’Connor JM, Hannigan BM, Strain JJ. The immune system as a physiological indicator of marginal copper status? Br J Nutr. 2002;87(5):393-403.

Dragutinovic VV, Tatic SB, Nikolic-Mandic SD, Tripkovic TM, Dunderovic DM, Paunovic IR. Copper as ancillary diagnostic tool in preoperative evaluation of possible papillary thyroid carcinoma in patients with benign thyroid disease. Biol Trace Elem Res. 2014;160(3):311-5.

Kucharzewski M, Braziewicz J, Majewska U, Gozdz S. Copper, zinc, and selenium in whole blood and thyroid tissue of people with various thyroid diseases. Biol Trace Elem Res. 2003;93(1-3):9-18.

Leung PL, Li XL. Multielement analysis in serum of thyroid cancer patients before and after a surgical operation. Biol Trace Elem Res. 1996;51(3):259-66.

Kosova F, Cetin B, Akinci M, Aslan S, Seki A, Pirhan Y, et al. Serum copper levels in benign and malignant thyroid diseases. Bratisl Lek Listy. 2012;113(12):718-20.

Baltaci AK, Dundar TK, Aksoy F, Mogulkoc R. Changes in the Serum Levels of Trace Elements Before and After the Operation in Thyroid Cancer Patients. Biol Trace Elem Res. 2017;175(1):57-64.

Al-Sayer H, Mathew TC, Asfar S, Khourshed M, Al-Bader A, Behbehani A, et al. Serum changes in trace elements during thyroid cancers. Mol Cell Biochem. 2004;260(1-2):1-5.

Rojanamatin J, Ukranun W, Supaattagorn P, Chiawiriyabunya I, Wongsena M, Chaiwerawattana A. Cancer in Thailand. Vol.X, 2016-2018. Bangkok, Thailand: National Cancer Institute; 2021.

Zhang HQ, Li N, Zhang Z, Gao S, Yin HY, Guo DM, et al. Serum zinc, copper, and zinc/copper in healthy residents of Jinan. Biol Trace Elem Res. 2009;131(1):25-32.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-9.

Lockitch G, Fassett J, Gerson B, Nixon D, Parsons P, Savory J. Control of Pre-Analytical Variation in Trace Element Determinations; Approved Guideline. NCCLS document C38-A. J National Committee for Clinical Laboratory Standards Wayne, PA. 1997:30.

Przybylik-Mazurek E, Zagrodzki P, Kuzniarz-Rymarz S, Hubalewska-Dydejczyk A. Thyroid disorders-assessments of trace elements, clinical, and laboratory parameters. Biol Trace Elem Res. 2011;141(1-3):65-75.

Li Y. Copper homeostasis: Emerging target for cancer treatment. J IUBMB life. 2020;72(9):1900-8.

Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, et al. Copper is required for oncogenic BRAF signaling and tumorigenesis. Nature. 2014;509(7501):492-6.

Baldari S, Di Rocco G, Heffern MC, Su TA, Chang CJ, Toietta G. Effects of Copper Chelation on BRAF(V600E) Positive Colon Carcinoma Cells. Cancers (Basel). 2019;11(5):659.

Stojsavljević A, Rovčanin B. Impact of Essential and Toxic Trace Metals on Thyroid Health and Cancer: A Review. Exposure and Health 2021;13:613-27.